Progress in the treatment of intracranial multidrug-resistant and extensively drug-resistant <i>Acinetobacter baumannii</i> infection_West China Medical Journal

Authors：

ZHAO Nan , SHAO Dongchuan , WANG Zeyi , ZHANG Wencai ,  MA Gang

Department of Neurosurgery, the First Hospital of Kunming, Kunming, Yunnan 650021, P. R. China;

Corresponding author：

MA Gang, Email: 2198451485@qq.com

Keywords：

Intracranial infection; Acinetobacter baumannii; Drug-resistance; Treatment

DOI：

10.7507/1002-0179.202004406

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Intracranial Acinetobacter baumannii infection is a rare clinical disease with a gradual increase in incidence and extremely high mortality. With the continuous enhancement of bacterial resistance, more and more intracranial infections of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii have appeared in the clinic, and its treatment has become a major challenge and problem faced by neurosurgeons. The treatment difficulties include the selection, usage and dosage of antimicrobial agents, as well as whether cerebrospinal fluid drainage is needed. A standardized treatment plan is still needed. In this paper, combining domestic and foreign literature, the treatment of intracranial infection of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii will be reviewed in order to provide a reference for clinical treatment.

Citation： ZHAO Nan, SHAO Dongchuan, WANG Zeyi, ZHANG Wencai, MA Gang. Progress in the treatment of intracranial multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infection. West China Medical Journal, 2021, 36(8): 1115-1119. doi: 10.7507/1002-0179.202004406 Copy

1.	Chen CH, Chang CY, Lin LJ, et al. Risk factors associated with postcraniotomy meningitis: a retrospective study. Medicine (Baltimore), 2016, 95(31): e4329.
2.	Schiaroli E, Pasticci MB, Cassetta MI, et al. Management of meningitis caused by multi drug-resistant Acinetobacter baumannii: clinical, microbiological and pharmacokinetic results in a patient treated with colistin methanesulfonate. Mediterr J Hematol Infect Dis, 2015, 7(1): e2015055.
3.	Piparsania S, Rajput N, Bhatambare G. Intraventricular polymyxin B for the treatment of neonatal meningo-ventriculitis caused by multi-resistant Acinetobacter baumannii--case report and review of literature. Turk J Pediatr, 2012, 54(5): 548-554.
4.	Karaiskos I, Galani L, Baziaka F, et al. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents, 2013, 41(6): 499-508.
5.	Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis, 2009, 9(4): 245-255.
6.	周华, 周建英, 俞云松. 中国鲍曼不动杆菌感染诊治与防控专家共识解读. 中国循证医学杂志, 2016, 16(1): 26-29.
7.	Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs, 2013, 15(2): 93-117.
8.	Jafarnejad S, Shab-Bidar S, Speakman JR, et al. Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18-64 years) but not the elderly (> 65 years): a meta-analysis. Nutr Clin Pract, 2016, 31(4): 502-513.
9.	Cohen-Pfeffer JL, Gururangan S, Lester T, et al. Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol, 2017, 67: 23-35.
10.	高建国, 叶英. 鲍曼不动杆菌颅内感染临床特征与预后危险因素分析. 中华医学杂志, 2018, 98(37): 2973-2977.
11.	Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev, 2010, 23(4): 858-883.
12.	Cawley MJ, Suh C, Lee S, et al. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy, 2002, 22(4): 527-532.
13.	Sun L, Wang X, Li Z. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin sulbactam in primary hospital. Br J Neurosurg, 2018, 32(6): 642-645.
14.	徐亦农, 张闻闻, 孙吉林, 等. 1例多重耐药鲍曼不动杆菌致颅内感染的治疗体会. 感染、炎症、修复, 2016, 17(1): 44-45.
15.	Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother, 2006, 58(6): 1221-1229.
16.	Tutuncu EE, Kuscu F, Gurbuz Y, et al. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis, 2010, 14(Suppl 3): e224-e226.
17.	Sipahi OR, Mermer S, Demirdal T, et al. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: results of the ege study. Clin Neurol Neurosurg, 2018, 172: 31-38.
18.	Lauretti L, D’Alessandris QG, Fantoni M, et al. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg, 2017, 127(2): 370-373.
19.	Fang YQ, Zhan RC, Jia W, et al. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine (Baltimore), 2017, 96(31): e7703.
20.	Long W, Yuan J, Liu J, et al. Multidrug resistant brain abscess due to Acinetobacter baumannii ventriculitis cleared by intraventricular and intravenous tigecycline therapy: a case report and review of literature. Front Neurol, 2018, 9: 518.
21.	焦永成, 孔海波, 刘爱军, 等. 替加环素鞘内注射治疗多重耐药鲍曼不动杆菌颅内感染. 临床神经外科杂志, 2020, 17(1): 90-93.
22.	Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med, 2015, 41(12): 2057-2075.
23.	Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis, 2017, 64(6): e34-e65.
24.	王明贵. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制: 中国专家共识. 中国感染与化疗杂志, 2017, 17(1): 82-93.
25.	Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother, 2009, 53(11): 4907-4910.
26.	Benifla M, Zucker G, Cohen A, et al. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother, 2004, 54(1): 290-292.
27.	Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents, 2007, 29(1): 9-25.
28.	Rodríguez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother, 2008, 61(4): 908-913.
29.	Cascio A, Conti A, Sinardi L, et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis, 2010, 14(7): e572-e579.
30.	Moon C, Kwak YG, Kim BN, et al. Implications of postneurosurgical meningitis caused by carbapenem-resistant Acinetobacter baumannii. J Infect Chemother, 2013, 19(5): 916-919.
31.	Guo W, Guo SC, Li M, et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline - a case report. Antimicrob Resist Infect Control, 2018, 7: 22.
32.	Ye J, Tan LH, Shen ZP, et al. Polymyxin for the treatment of intracranial infections of extensively drug-resistant bacteria in children after neurosurgical operation. World J Pediatr, 2020, 16(5): 528-532.
33.	Pan S, Huang X, Wang Y, et al. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study. Antimicrob Resist Infect Control, 2018, 7: 8.
34.	Fotakopoulos G, Makris D, Chatzi M, et al. Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin. Acta Neurochir (Wien), 2016, 158(3): 603-610.
35.	De Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol, 2016, 23(1): 68-75.
36.	Chusri S, Sakarunchai I, Kositpantawong N, et al. Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents, 2018, 51(4): 646-650.
37.	Pandey S, Li L, Deng XY, et al. Outcome following the treatment of ventriculitis caused by multi/extensive drug resistance gram negative bacilli; Acinetobacter baumannii and Klebsiella pneumonia. Front Neurol, 2019, 9: 1174.
38.	车江鹏, 黄瑾, 茆长玥, 等. 静脉联合鞘内或脑室内注射多黏菌素对多重耐药鲍曼不动杆菌颅内感染疗效及安全性meta分析. 中国抗生素杂志, 2020, 45(9): 929-934.
39.	Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis, 2004, 39(9): 1267-1284.
40.	Ng J, Gosbell IB, Kelly JA, et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother, 2006, 58(5): 1078-1081.
41.	夏博铭, 朱磊, 张恒柱, 等. 多途径联合用药治疗广泛耐药鲍曼不动杆菌颅内感染1例报告并文献复习. 临床神经外科杂志, 2019, 16(3): 266-269.
42.	Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther, 2013, 11(12): 1333-1353.
43.	裴红莎, 刘宝来, 聂晓奇, 等. 磷霉素和头孢哌酮/舒巴坦钠序贯疗法治疗颅内多重耐药鲍曼不动杆菌感染的临床分析. 中国临床神经外科杂志, 2016, 21(4): 232-233.
44.	Wu X, Wang L, Ye YZ, et al. Postoperative multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intravenous doxycycline and intraventricular gentamicin: a case report. World J Clin Cases, 2019, 7(24): 4342-4348.
45.	Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis, 2010, 23(4): 332-339.
46.	杨林, 秦逊, 向琰, 等. 腰大池引流加鞘内注射治疗泛耐药鲍曼不动杆菌颅内感染的临床疗效分析. 国际神经病学神经外科学杂志, 2020, 47(3): 263-267.

1. Chen CH, Chang CY, Lin LJ, et al. Risk factors associated with postcraniotomy meningitis: a retrospective study. Medicine (Baltimore), 2016, 95(31): e4329.
2. Schiaroli E, Pasticci MB, Cassetta MI, et al. Management of meningitis caused by multi drug-resistant Acinetobacter baumannii: clinical, microbiological and pharmacokinetic results in a patient treated with colistin methanesulfonate. Mediterr J Hematol Infect Dis, 2015, 7(1): e2015055.
3. Piparsania S, Rajput N, Bhatambare G. Intraventricular polymyxin B for the treatment of neonatal meningo-ventriculitis caused by multi-resistant Acinetobacter baumannii--case report and review of literature. Turk J Pediatr, 2012, 54(5): 548-554.
4. Karaiskos I, Galani L, Baziaka F, et al. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents, 2013, 41(6): 499-508.
5. Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis, 2009, 9(4): 245-255.
6. 周华, 周建英, 俞云松. 中国鲍曼不动杆菌感染诊治与防控专家共识解读. 中国循证医学杂志, 2016, 16(1): 26-29.
7. Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs, 2013, 15(2): 93-117.
8. Jafarnejad S, Shab-Bidar S, Speakman JR, et al. Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18-64 years) but not the elderly (> 65 years): a meta-analysis. Nutr Clin Pract, 2016, 31(4): 502-513.
9. Cohen-Pfeffer JL, Gururangan S, Lester T, et al. Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol, 2017, 67: 23-35.
10. 高建国, 叶英. 鲍曼不动杆菌颅内感染临床特征与预后危险因素分析. 中华医学杂志, 2018, 98(37): 2973-2977.
11. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev, 2010, 23(4): 858-883.
12. Cawley MJ, Suh C, Lee S, et al. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy, 2002, 22(4): 527-532.
13. Sun L, Wang X, Li Z. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin sulbactam in primary hospital. Br J Neurosurg, 2018, 32(6): 642-645.
14. 徐亦农, 张闻闻, 孙吉林, 等. 1例多重耐药鲍曼不动杆菌致颅内感染的治疗体会. 感染、炎症、修复, 2016, 17(1): 44-45.
15. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother, 2006, 58(6): 1221-1229.
16. Tutuncu EE, Kuscu F, Gurbuz Y, et al. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis, 2010, 14(Suppl 3): e224-e226.
17. Sipahi OR, Mermer S, Demirdal T, et al. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: results of the ege study. Clin Neurol Neurosurg, 2018, 172: 31-38.
18. Lauretti L, D’Alessandris QG, Fantoni M, et al. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg, 2017, 127(2): 370-373.
19. Fang YQ, Zhan RC, Jia W, et al. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine (Baltimore), 2017, 96(31): e7703.
20. Long W, Yuan J, Liu J, et al. Multidrug resistant brain abscess due to Acinetobacter baumannii ventriculitis cleared by intraventricular and intravenous tigecycline therapy: a case report and review of literature. Front Neurol, 2018, 9: 518.
21. 焦永成, 孔海波, 刘爱军, 等. 替加环素鞘内注射治疗多重耐药鲍曼不动杆菌颅内感染. 临床神经外科杂志, 2020, 17(1): 90-93.
22. Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med, 2015, 41(12): 2057-2075.
23. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis, 2017, 64(6): e34-e65.
24. 王明贵. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制: 中国专家共识. 中国感染与化疗杂志, 2017, 17(1): 82-93.
25. Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother, 2009, 53(11): 4907-4910.
26. Benifla M, Zucker G, Cohen A, et al. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother, 2004, 54(1): 290-292.
27. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents, 2007, 29(1): 9-25.
28. Rodríguez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother, 2008, 61(4): 908-913.
29. Cascio A, Conti A, Sinardi L, et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis, 2010, 14(7): e572-e579.
30. Moon C, Kwak YG, Kim BN, et al. Implications of postneurosurgical meningitis caused by carbapenem-resistant Acinetobacter baumannii. J Infect Chemother, 2013, 19(5): 916-919.
31. Guo W, Guo SC, Li M, et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline - a case report. Antimicrob Resist Infect Control, 2018, 7: 22.
32. Ye J, Tan LH, Shen ZP, et al. Polymyxin for the treatment of intracranial infections of extensively drug-resistant bacteria in children after neurosurgical operation. World J Pediatr, 2020, 16(5): 528-532.
33. Pan S, Huang X, Wang Y, et al. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study. Antimicrob Resist Infect Control, 2018, 7: 8.
34. Fotakopoulos G, Makris D, Chatzi M, et al. Outcomes in meningitis/ventriculitis treated with intravenous or intraventricular plus intravenous colistin. Acta Neurochir (Wien), 2016, 158(3): 603-610.
35. De Bonis P, Lofrese G, Scoppettuolo G, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol, 2016, 23(1): 68-75.
36. Chusri S, Sakarunchai I, Kositpantawong N, et al. Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents, 2018, 51(4): 646-650.
37. Pandey S, Li L, Deng XY, et al. Outcome following the treatment of ventriculitis caused by multi/extensive drug resistance gram negative bacilli; Acinetobacter baumannii and Klebsiella pneumonia. Front Neurol, 2019, 9: 1174.
38. 车江鹏, 黄瑾, 茆长玥, 等. 静脉联合鞘内或脑室内注射多黏菌素对多重耐药鲍曼不动杆菌颅内感染疗效及安全性meta分析. 中国抗生素杂志, 2020, 45(9): 929-934.
39. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis, 2004, 39(9): 1267-1284.
40. Ng J, Gosbell IB, Kelly JA, et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother, 2006, 58(5): 1078-1081.
41. 夏博铭, 朱磊, 张恒柱, 等. 多途径联合用药治疗广泛耐药鲍曼不动杆菌颅内感染1例报告并文献复习. 临床神经外科杂志, 2019, 16(3): 266-269.
42. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther, 2013, 11(12): 1333-1353.
43. 裴红莎, 刘宝来, 聂晓奇, 等. 磷霉素和头孢哌酮/舒巴坦钠序贯疗法治疗颅内多重耐药鲍曼不动杆菌感染的临床分析. 中国临床神经外科杂志, 2016, 21(4): 232-233.
44. Wu X, Wang L, Ye YZ, et al. Postoperative multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intravenous doxycycline and intraventricular gentamicin: a case report. World J Clin Cases, 2019, 7(24): 4342-4348.
45. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis, 2010, 23(4): 332-339.
46. 杨林, 秦逊, 向琰, 等. 腰大池引流加鞘内注射治疗泛耐药鲍曼不动杆菌颅内感染的临床疗效分析. 国际神经病学神经外科学杂志, 2020, 47(3): 263-267.

Previous Article
Mechanism of Epstein-Barr virus latent infection-related genes in tumors caused by them
Next Article
Virtual reality for the upper limb motor rehabilitation after stroke

West China Medical Journal

Progress in the treatment of intracranial multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infection

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content